1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kyongbo Pharmaceutical Co., Ltd.

Kyongbo Pharmaceutical Co., Ltd.

KKRX:214390
5,130.00
KRW
-100.00
(-1.91%)
210.79EPS
24.48P/E
123.36BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7,883.59
7,821
7,803.57
8,012.87
8,427.66
8,016.11
8,996.49
7,149.55
8,357.3
9,019.74
9,975.56
11,590.3
11,684.22
Basic EPS, GAAP
401
1,147
531
751
549
221
393
-314
26
124
194
8
210.79
Free Cash Flow per Basic Share
-150.37
-1,011.3
235.9
769.61
-390.64
17.64
349.3
-14.9
-130.18
-251.5
-544.7
-1,499.06
-1,896.41
Dividend per Share
299.72
283.56
274.75
199.9
250.17
199.93
99.9
100.15
50.9
49.83
49.98
52.46
- -
Book Value per Share
2,858.17
5,137.32
5,412.77
5,919.2
6,233.03
6,239.36
6,527.7
6,094.52
6,011
6,039.33
6,113.48
6,096.06
6,148.48
Tangible Book Value per Share
2,771.63
5,068.54
5,272.62
5,811.11
6,128.48
6,093.69
6,398.43
5,954.19
5,876.26
5,887.05
5,945.84
5,933.76
5,939.98
Basic Weighted Avg Shares
22
23
24
24
24
24
24
24
23
24
24
23
24
Sales/Revenue/Turnover
169,781
178,033
186,726
191,661
201,344
191,706
215,285
170,660
196,265
216,357
238,556
264,104
279,552
Operating Margin (%)
16.3
14.4
8.35
12.83
8.58
3.23
4.02
-3.88
0.71
2.56
4.38
1.33
0.94
Depreciation Expense
7,203
8,279
10,440
11,467
11,558
12,589
12,588
12,757
11,936
11,699
12,408
13,204
14,108
Net Income, GAAP
8,636
26,110
12,706
17,963
13,116
5,285
9,404
-7,495
611
2,974
4,639
182
5,043
Effective Tax Rate (%)
71.25
- -
18.78
25.96
25.66
24.3
32.97
- -
- -
- -
5.38
59.44
15.6
Profit Margin (%)
5.09
14.67
6.8
9.37
6.51
2.76
4.37
-4.39
0.31
1.37
1.94
0.07
1.8
Working Capital
11,861
40,566
29,510
50,259
59,618
40,362
44,429
22,352
20,757
17,641
19,281
11,889
-23,646
LT Debt
10,000
5,000
- -
451
451
1,910
1,192
476
242
1,674
1,043
24,340
25,635
Total Equity
68,330
122,817
129,402
141,510
149,012
149,164
156,057
145,701
143,704
144,381
146,154
145,738
146,991
Return on Invested Capital (%)
- -
- -
7.64
10.62
7.08
2.39
2.76
- -
- -
- -
4.35
0.56
0.8
Return on Capital (%)
- -
- -
8.11
10.98
7.61
3.16
4.84
- -
- -
- -
3.8
0.75
1.8
Return on Common Equity (%)
- -
27.32
10.08
13.26
9.03
3.55
6.16
-4.97
0.42
2.06
3.19
0.12
3.49

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
102,331
117,298
132,366
LT Borrowings
24,000
24,000
24,000
LT Finance Leases
340
1,731
1,635
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
24
Market Capitalization
137,943
171,173
123,359

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
159,138
156,920
169,900
Cash, Cash Equivalents & STI
8,048
9,951
13,828
Accounts Receivable, Net
63,268
63,088
70,755
Inventories
80,977
77,546
76,560
Total Current Liabilities
147,249
166,931
193,546
Payables & Accruals
- -
- -
- -
ST Debt
102,331
117,298
132,366
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.81%
-1.32%
-0.28%
Free Cash Flow
275.82%
206.19%
162.24%
Net Income, GAAP
4.05%
11.84%
-96.07%
Sales/Revenue/Turnover
4.56%
5.1%
10.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62,600
58,411
58,231
59,314
238,556
2025
60,588
65,313
66,987
71,216
264,104
2026
66,127
75,222
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
7
45
73.27
194
2025
-29
-73
126.82
-18.1
8
2026
-22.16
124
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
49.98
2025
- -
- -
- -
- -
52.46
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tae-Young Kim
Full Time Employees
571
Sector
Health technology
Industry
Pharmaceuticals: major
Address
174, Sirok-ro Asan-si SC South Korea
IPO Date
Jun 29, 2015
Website
kbpharma.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients, finished drugs, and related medical products primarily in South Korea with exports to approximately 30 countries worldwide. The company produces general APIs, cephalosporins APIs including sterile and non-sterile cephalosporin intermediates such as 7-DMT for Cefotiam and 7-GNCA for Ceftizoxime and Ceftibuten, anti-cancer APIs, high potency and cytotoxic APIs including those for carbapenem and cephalosporin injectables, and cardiovascular APIs such as Clopidogrel, Amlodipine besylate, and Atorvastatin calcium; prescription drugs encompassing anesthetics, cardiovascular treatments, digestive agents like Esomeprazole, antibiotics, and anti-psychotics such as Donepezil; over-the-counter drugs; finished solid oral dosage forms; cephalosporin injectable drugs in sterile medical vials; and medical devices including portable X-ray machines, ultrasonic diagnostic equipment, extracorporeal shockwave therapy systems, and temperature control probes. It also engages in contract development and manufacturing organization services, cGMP synthesis, raw materials supply, drug development, project management, and research and development of anti-viral drugs such as Entecavir and anti-cancer drugs like Imatinib. Founded in 1987 and headquartered at 174, Sirok-ro, Asan-si, Chungcheongnam-do, South Korea, with additional facilities including a Seoul office, laboratories in Asan-si, and a New Drug Research Center in Yongin-si, the company listed on the KOSPI exchange in June 2015 under ticker 214390.KS and employs 518 people as of late 2023. Formerly known as Kyongbo Chemical Co., Ltd., it changed its name in March 2002 to reflect its focus on pharmaceuticals; recent activities include ongoing expansion of specialized manufacturing plants for anticancer and sterile APIs, as well as sustained investment in its research center established in 1988 to develop top-tier APIs.